Flash finding: 28% of all COVID-19 drug trials involve chloroquine products

For the past few weeks, we have been tracking the number of COVID-19 trials on ClinicalTrials.gov, with specific emphasis on drug trials. As of Tuesday, the week-over-week number of drug trials increased by 101 to a total of 431, and the number of different active ingredients undergoing trials for COVID-19 is now up to 190. When digging into those numbers, we found that the chloroquine/hydroxychloroquine craze appears to have spilled over to the research community, launching 124 trials on these two drugs – a staggering 28% of the total drug trials, as of today.

Ben LinkApril 30, 2020COVID, Clinical Trial, Chloroquine, Hydroxychloroquine, Remdesivir

Track the prices of investigational drugs for COVID-19

COVID-19 has dominated all aspects of American and international life over the past months. As the scope of the disease becomes more apparent by the day, we have begun to monitor the impact that COVID-19 has had on prescription drug prices, and unsurprisingly, there’s been volatility. To facilitate broader investigation into the impact COVID-19, we wanted to share within the public domain the list of national drug codes (NDCs) that included active ingredients currently being investigated in conjunction with COVID-19 according to ClinicalTrials.gov. This new tool will give users the ability to better track prices of drugs that are being evaluated as potential treatments options. Here’s how we did it, and how you can use it.

Ben LinkApril 14, 2020COVID, Clinical Trial, Deferoxamine, Desferal